First-Line Atezolizumab Plus Bevacizumab Receives Breakthrough Therapy Designation for HCC

Share this content:
Twenty-three systemic therapy-naive patients with advanced hepatocellular carcinoma received atezolizumab plus bevacizumab every 3 weeks.
Twenty-three systemic therapy-naive patients with advanced hepatocellular carcinoma received atezolizumab plus bevacizumab every 3 weeks.

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to atezolizumab and bevacizumab combination therapy as a first-line option for the treatment of patients with advanced or metastatic hepatocellular carcinoma (HCC), according to a press release.1

The FDA based its decision on results from a multicenter phase 1b (ClinicalTrials.gov Identifier: NCT02715531) study, for which researchers randomly assigned patients to 5 different treatment arms. Twenty-three evaluable, systemic therapy-naive patients with advanced HCC were assigned to arm A and received atezolizumab 1200 mg plus bevacizumab 15 mg/kg every 3 weeks.

After a median follow-up of 10.3 months, an independent review facility analysis showed that 65% (23) of patients had a response to treatment. All subgroups exhibited a response regardless of the etiology of their disease (eg, Hepatitis B, Hepatitis C, non-viral), region, high versus low baseline alpha-fetoprotein levels, or spread of tumor beyond the liver. Investigator assessments showed a response rate of 61% (14 patients).

Median duration of response, overall survival, progression-free survival, and time-to-progression were not yet evaluable at the current analysis.

In the safety evaluable population of 43 patients, grade 3 to 4 treatment-related adverse events (AE) were observed in 28% (12) of patients; no grade 5 AEs were reported.

Breakthrough therapy designation is granted to shorten the development and review period for therapies that treat serious or life-threatening conditions with limited treatment options.

Reference

  1. FDA grants Breakthrough Therapy Designation for Roche's Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC) [press release]. Basel, Switzerland; Roche; July 18, 2018. http://hugin.info/174806/R/2205644/857058.pdf. Accessed July 18, 2018.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs